Baseline characteristics, disease characteristics and biomarkers at VENTURE baseline
| VENTURE baseline OCS dose ≤10 mg·day−1 | VENTURE baseline OCS dose >10 mg·day−1 | |||
| Placebo/DPL | DPL/DPL | Placebo/DPL | DPL/DPL | |
| Patients | 61 | 60 | 36 | 30 |
| Age, years | 50.9±12.0 | 53.5±12.0 | 52.1±13.0 | 48.0±14.0 |
| Male | 26 (42.6) | 25 (41.7) | 14 (38.9) | 12 (40.0) |
| Ongoing atopic or allergic condition# | 43 (70.5) | 44 (73.3) | 28 (77.8) | 21 (70.0) |
| Former smoker | 13 (21.3) | 16 (26.7) | 2 (5.6) | 3 (10.0) |
| OCS dose, mg·day−1 | 8.07 (2.06) | 7.42 (2.16) | 17.57 (5.69) | 18.08 (5.40) |
| Number of severe asthma exacerbations in the 1 year prior to parent study | 2.30 (2.19) | 1.87 (2.17) | 1.97 (2.52) | 1.97 (1.45) |
| Pre-bronchodilator FEV1, L | 1.62±0.66 | 1.50±0.48 | 1.63±0.57 | 1.58±0.55 |
| Pre-bronchodilator FEV1, % predicted | 51.6±16.0 | 51.6±15.2 | 53.9±14.6 | 52.1±15.9 |
| FEV1 reversibility, % | 18.6±25.2 | 22.6±26.4 | 16.9±20.7 | 20.2±20.0 |
| ACQ-5 score, scale 0–6 | 2.54±1.14 | 2.39±1.18 | 2.69±1.06 | 2.53±1.05 |
| AQLQ global score, scale 1–7 | 4.43±1.11 | 4.41±1.08 | 4.19±1.17 | 4.26±1.26 |
| Blood eosinophils, cells·µL−1 | 250 (110.0–430.0) | 340 (180–545.0) | 220 (115.0–430.00) | 210 (140.0–320.0) |
| Total IgE, IU·mL−1 | 140.0 (36.0–494.5) | 185.5 (103.5–484.5) | 161.0 (48.0–304.5) | 131.0 (40.0–588.0) |
| FENO, ppb | 21.0 (15.0–44.0) | 28.0 (14.0–47.0) | 41.0 (26.0–67.0) | 26.0 (16.0–42.0) |
Data are presented as n, mean±sd, n (%) or median (interquartile range). OCS: oral corticosteroids; DPL: dupilumab; FEV1: forced expiratory volume in 1 s; ACQ-5: five-item Asthma Control Questionnaire; AQLQ: Asthma Quality of Life Questionnaire; IgE: immunoglobulin E; FENO: fractional exhaled nitric oxide. #: a patient who has any of the following diseases: atopic dermatitis, allergic conjunctivitis or rhinitis, eosinophilic oesophagitis, food allergy or hives, or if baseline total IgE ≥100 IU·mL−1 and at least one aeroantigen-specific IgE is positive (≥0.35 IU·mL−1) at baseline.